ACXP
Acurx Pharmaceuticals, Inc.
Biotechnology
Market Cap$5M
5Y Perf.-98.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ACXP vs NAOV
Revenue, margins, valuation, and 5-year total return — side by side.
NAOV
NanoVibronix, Inc.
Medical - Devices
Market Cap$513K
5Y Perf.-99.8%
ACXP vs NAOV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ACXP | NAOV |
|---|---|---|
| Industry | Biotechnology | Medical - Devices |
| Market Cap | $5M | $513K |
| Revenue (TTM) | $0.00 | $3M |
| Net Income (TTM) | $-7.97B | $-4M |
| Gross Margin | — | 30.0% |
| Operating Margin | — | -351.8% |
| Total Debt | $0.00 | $116K |
| Cash & Equiv. | $7.56B | $752K |
ACXP vs NAOV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ACXP
NAOV
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Acurx Pharmaceutica… (ACXP) | 100 | 1.7 | -98.3% |
| NanoVibronix, Inc. (NAOV) | 100 | 0.2 | -99.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACXP vs NAOV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NAOV leads in 2 of 4 categories, making it the strongest pick for capital preservation and lower volatility and operational efficiency and capital deployment. Acurx Pharmaceuticals, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ACXP
Acurx Pharmaceuticals, Inc.
The Growth Play
ACXP is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 69.8%
- -98.7% 10Y total return vs NAOV's -100.0%
- -70.1% vs NAOV's -95.7%
Best for: growth exposure and long-term compounding
NAOV
NanoVibronix, Inc.
The Income Pick
NAOV carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.49
- Lower volatility, beta 1.49, Low D/E 18.5%, current ratio 1.22x
- Beta 1.49, current ratio 1.22x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | NAOV | Beta 1.49 vs ACXP's 2.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACXP | -70.1% vs NAOV's -95.7% |
| Efficiency (ROA) | NAOV | -6.6% ROA vs ACXP's -413.5% |
ACXP vs NAOV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACXPLAGGINGNAOV
NAOVNanoVibronix, Inc.
1leads
ACXPAcurx Pharmaceuticals…
3leads
6 Total Categories
CATEGORYLEADERvs NAOVMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NAOV1/1
Valuation MetricsMultiples, price ratios, and targets
ACXP2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACXP3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ACXP5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NAOV leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NAOV and ACXP operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | ACXPAcurx Pharmaceuti… | NAOVNanoVibronix, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $3M |
| EBITDAEarnings before interest/tax | $35,910 | -$9M |
| Net IncomeAfter-tax profit | -$8.0B | -$4M |
| Free Cash FlowCash after capex | $4.6B | -$7M |
| Gross MarginGross profit ÷ Revenue | — | +30.0% |
| Operating MarginEBIT ÷ Revenue | — | -3.5% |
| Net MarginNet income ÷ Revenue | — | -133.0% |
| FCF MarginFCF ÷ Revenue | — | -2.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +92.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +98.2% | +129.2% |
NAOV leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ACXP leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ACXPAcurx Pharmaceuti… | NAOVNanoVibronix, Inc. |
|---|---|---|
| Market CapShares × price | $5M | $512,711 |
| Enterprise ValueMkt cap + debt − cash | -$7.6B | -$123,289 |
| Trailing P/EPrice ÷ TTM EPS | -0.40x | -0.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.20x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.82x |
| Price / FCFMarket cap ÷ FCF | — | — |
ACXP leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ACXP leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
NAOV delivers a -8.4% return on equity — every $100 of shareholder capital generates $-8 in annual profit, vs $-6 for ACXP. On the Piotroski fundamental quality scale (0–9), ACXP scores 3/9 vs NAOV's 2/9, reflecting mixed financial health.
| Metric | ACXPAcurx Pharmaceuti… | NAOVNanoVibronix, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -6.0% | -8.4% |
| ROA (TTM)Return on assets | -4.1% | -6.6% |
| ROICReturn on invested capital | — | -7.7% |
| ROCEReturn on capital employed | — | -139.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.19x |
| Net DebtTotal debt minus cash | -$7.6B | -$636,000 |
| Cash & Equiv.Liquid assets | $7.6B | $752,000 |
| Total DebtShort + long-term debt | $0 | $116,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -23.76x |
ACXP leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ACXP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACXP five years ago would be worth $134 today (with dividends reinvested), compared to $9 for NAOV. Over the past 12 months, ACXP leads with a -70.1% total return vs NAOV's -95.7%. The 3-year compound annual growth rate (CAGR) favors ACXP at -67.4% vs NAOV's -83.3% — a key indicator of consistent wealth creation.
| Metric | ACXPAcurx Pharmaceuti… | NAOVNanoVibronix, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -23.2% | -22.4% |
| 1-Year ReturnPast 12 months | -70.1% | -95.7% |
| 3-Year ReturnCumulative with dividends | -96.5% | -99.5% |
| 5-Year ReturnCumulative with dividends | -98.7% | -99.9% |
| 10-Year ReturnCumulative with dividends | -98.7% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -67.4% | -83.3% |
ACXP leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ACXP and NAOV each lead in 1 of 2 comparable metrics.
Risk & Volatility
NAOV is the less volatile stock with a 1.49 beta — it tends to amplify market swings less than ACXP's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACXP currently trades 10.1% from its 52-week high vs NAOV's 4.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ACXPAcurx Pharmaceuti… | NAOVNanoVibronix, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.42x | 1.49x |
| 52-Week HighHighest price in past year | $21.00 | $44.50 |
| 52-Week LowLowest price in past year | $1.33 | $0.99 |
| % of 52W HighCurrent price vs 52-week peak | +10.1% | +4.3% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 45.1 |
| Avg Volume (50D)Average daily shares traded | 3.6M | 335K |
Evenly matched — ACXP and NAOV each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ACXPAcurx Pharmaceuti… | NAOVNanoVibronix, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACXP leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). NAOV leads in 1 (Income & Cash Flow). 1 tied.
Best OverallAcurx Pharmaceuticals, Inc. (ACXP)Leads 3 of 6 categories
Loading custom metrics...
ACXP vs NAOV: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — ACXP or NAOV?
Over the past 5 years, Acurx Pharmaceuticals, Inc.
(ACXP) delivered a total return of -98. 7%, compared to -99. 9% for NanoVibronix, Inc. (NAOV). Over 10 years, the gap is even starker: ACXP returned -98. 7% versus NAOV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ACXP or NAOV?
By beta (market sensitivity over 5 years), NanoVibronix, Inc.
(NAOV) is the lower-risk stock at 1. 49β versus Acurx Pharmaceuticals, Inc. 's 2. 42β — meaning ACXP is approximately 62% more volatile than NAOV relative to the S&P 500.
03Which is growing faster — ACXP or NAOV?
On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc.
grew EPS 69. 8% year-over-year, compared to 35. 2% for NanoVibronix, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — ACXP or NAOV?
Acurx Pharmaceuticals, Inc.
(ACXP) is the more profitable company, earning 0. 0% net margin versus -144. 8% for NanoVibronix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACXP leads at 0. 0% versus -140. 0% for NAOV. At the gross margin level — before operating expenses — NAOV leads at 59. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ACXP or NAOV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ACXP or NAOV better for a retirement portfolio?
For long-horizon retirement investors, NanoVibronix, Inc.
(NAOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NAOV: -100. 0%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ACXP and NAOV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.